AbbVie, Inc. (ABBV)
295.01
+0.56
(+0.19%)
USD |
NYSE |
Nov 13, 16:00
294.41
-0.60
(-0.20%)
After-Hours: 19:59
AbbVie Enterprise Value : 590.62B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 590.62B |
| November 11, 2026 | 591.55B |
| November 10, 2026 | 589.63B |
| November 09, 2026 | 588.58B |
| November 06, 2026 | 585.07B |
| November 05, 2026 | 579.64B |
| November 04, 2026 | 591.29B |
| November 03, 2026 | 575.68B |
| November 02, 2026 | 580.70B |
| October 30, 2026 | 591.39B |
| October 29, 2026 | 584.15B |
| October 28, 2026 | 575.66B |
| October 27, 2026 | 576.37B |
| October 26, 2026 | 576.99B |
| October 23, 2026 | 575.05B |
| October 22, 2026 | 574.25B |
| October 21, 2026 | 573.56B |
| October 20, 2026 | 581.13B |
| October 19, 2026 | 569.81B |
| October 16, 2026 | 574.66B |
| October 15, 2026 | 571.09B |
| October 14, 2026 | 571.23B |
| October 13, 2026 | 555.11B |
| October 12, 2026 | 567.06B |
| October 09, 2026 | 558.84B |
| Date | Value |
|---|---|
| October 08, 2026 | 551.68B |
| October 07, 2026 | 549.81B |
| October 06, 2026 | 541.55B |
| October 05, 2026 | 539.91B |
| October 02, 2026 | 534.71B |
| October 01, 2026 | 529.60B |
| September 30, 2026 | 532.54B |
| September 29, 2026 | 529.55B |
| September 28, 2026 | 534.84B |
| September 25, 2026 | 531.41B |
| September 24, 2026 | 532.79B |
| September 23, 2026 | 532.71B |
| September 22, 2026 | 532.94B |
| September 21, 2026 | 531.65B |
| September 18, 2026 | 530.74B |
| September 17, 2026 | 530.84B |
| September 16, 2026 | 528.17B |
| September 15, 2026 | 529.11B |
| September 14, 2026 | 526.87B |
| September 11, 2026 | 518.65B |
| September 10, 2026 | 514.90B |
| September 09, 2026 | 507.68B |
| September 08, 2026 | 503.91B |
| September 04, 2026 | 517.48B |
| September 03, 2026 | 524.11B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biogen, Inc. | 43.52B |
| Gilead Sciences, Inc. | 226.62B |
| Regeneron Pharmaceuticals, Inc. | 91.75B |
| Amgen, Inc. | 293.45B |
| REGENXBIO, Inc. | 531.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.207B |
| Revenue (Quarterly) | 17.40B |
| Total Expenses (Quarterly) | 13.20B |
| EPS Diluted (Quarterly) | 2.373 |
| Gross Profit Margin (Quarterly) | 75.33% |
| Profit Margin (Quarterly) | 24.17% |
| Earnings Yield | 1.97% |
| Operating Earnings Yield | 4.57% |
| Normalized Earnings Yield | 3.177 |